Fennec Pharmaceuticals Reports Impressive Q1 2025 Results
~ Achieved Total Net Revenues of $8.8 Million, Reflecting an 18% Growth Year On Year ~
~ Positive Outcomes from an Enhanced Sales Strategy and Improved Patient Support Services ~
~ PEDMARQSI Now Available in Germany and the United Kingdom ~
Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX:FRX), a specialty pharmaceutical company, has reported significant financial results for the first quarter of 2025. This period showed total net revenues of approximately $8.8 million, up from $7.4 million in the previous year.
CEO Jeff Hackman emphasized the company’s strengthened focus in executing their strategic plan, particularly around their flagship products. The Q1 performance was buoyed by key engagements with PEDMARK accounts, benefiting from a newly enhanced patient support initiative known as Fennec HEARS™. This program aims to facilitate a better experience for patients undergoing treatment, specifically addressing the needs of teenage and young adult cancer patients.
Strategic Expansion and Business Highlights
During this quarter, Fennec Pharmaceuticals made notable advances across several initiatives:
Growth in PEDMARK Accounts
Fennec’s data-driven target lists improved effectiveness in reaching out to numerous academic and community healthcare providers. This approach contributed to the onboarding of various new accounts and expanded collaborations.
Revamped Patient Support Program
The company introduced improvements to the Fennec HEARS™ program, focusing on enhanced healthcare provider (HCP) support and increasing access to necessary nursing resources. This ensures that patients and providers have the assistance they need throughout the treatment journey.
PEDMARQSI Launch in Europe
The commercial launch of PEDMARQSI progressed with its introduction in Germany and recent endorsements in the UK. Steps have also been taken towards making this treatment available in Scotland through acceptance by the Scottish Medicines Consortium.
Events to Look Forward To
Fennec Pharmaceuticals is poised to participate in several key events:
American Society of Clinical Oncology (ASCO) Annual Meeting
The company will showcase its latest innovations at ASCO 2025 from May 30 to June 3 in Chicago, Illinois.
Annual Shareholder Meeting
All shareholders are invited to the Annual General Meeting on June 3, which will be accessible both in person and online. This presents an opportunity for stakeholders to engage with the leadership team regarding future plans and company performance.
Financial Overview for Q1 2025
A closer look at the financials reveals a solid foundation for future growth:
- Net Product Sales: The first quarter of 2025 yielded approximately $8.8 million in net product sales, marking an 18% increase compared to the same quarter last year.
- Selling and Marketing Expenses: Costs decreased to $2.9 million, down from $5.2 million in Q1 2024, reflecting a strategic reduction as the company streamlined its operations.
- General and Administrative Expenses: Expenses grew to $6.1 million over the same period, driven in part by non-cash stock-based compensation.
- Cash Position: The cash and cash equivalents declined to $22.6 million due to typical spending patterns associated with seasonal expenditures.
Understanding Cisplatin-Induced Ototoxicity
Cisplatin treatment, while effective against various malignancies, presents the significant risk of hearing loss, particularly in pediatric patients. The need for preventive measures is acute, as those affected often face long-term repercussions, necessitating interventions such as hearing aids or cochlear implants, which, while beneficial, do not reverse the damage.
PEDMARK, approved by the FDA, is the first therapy indicated for mitigating this risk in children receiving cisplatin. This program has had substantial success, showing data-backed efficacy and safety from previous clinical studies.
Fennec Pharmaceuticals: A Commitment to Quality Care
Fennec Pharmaceuticals remains steadfast in its mission to support patients facing the challenges of cancer treatment. The company's strategy aligns closely with its core values of patient care, scientific advancement, and community impact.
For further inquiries, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
Frequently Asked Questions
What are the financial results for Fennec Pharmaceuticals for Q1 2025?
Fennec reported net revenues of $8.8 million, which is an 18% year-over-year increase.
What is PEDMARK and what is its significance?
PEDMARK is a treatment approved by the FDA designed to reduce the risk of hearing loss in pediatric cancer patients undergoing cisplatin therapy.
What recent changes have been made to the Fennec HEARS™ program?
The program has been revamped to enhance support for providers and patients, ensuring better experiences for those treated with PEDMARK.
How has Fennec Pharmaceuticals expanded in Europe?
Fennec has launched PEDMARQSI in Germany and received acceptance for its use in Scotland, broadening access to treatment.
What future events is Fennec Pharmaceuticals participating in?
The company will be present at the ASCO Annual Meeting and will hold its Annual General Meeting to engage with stakeholders.
